SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the FDAs upcoming decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders citing the amended upper-limb data, rare-disease policy discussions and recent launch-related hiring as reasons for optimism. Others caution that approval is uncertain given the prior negative review and continuing questions about the evidence.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigens strong quarterly results and rapid PAPZIMEOS commercial uptake are driving attention, with traders highlighting the companys return to profitability and potential for further growth. The upbeat reaction is accompanied by short-squeeze speculation and interest in upcoming PRGN-2009 data and European expansion.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A run to a 52-week high has traders positioning around the expected Q3 earnings report, with BRIUMVIs sales growth supporting optimism. Buyout rumors and heavy short interest are fueling squeeze speculation, though some traders see earnings expectationsnot a confirmed acquisitionas the main driver.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths post-TDAPA Medicare add-on could fall sharply after Q1 2027 has fueled concerns about pricing and CorMedix revenue amid a steep selloff. Traders dispute whether DaVitas preliminary outlook signals a broader reimbursement decline, pointing to CMSs published estimate, while others criticize management for not clarifying the potential impact.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL leukemia trial reached its prespecified 80th death event, triggering final analysis and putting the GPS survival readout at the center of discussion. Traders are divided between optimism about a strong result and concerns about the control arm and trial design, while shares have come under pressure ahead of the binary catalyst.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is under pressure after a steep decline, with traders focused on analyst price-target cuts and uncertainty ahead of its earnings report, as well as concerns about digital-ad growth. Bulls argue the selloff is disconnected from the companys profitability and growth, while bears warn of more downside if results or guidance disappoint; some also point to broader tech-market weakness.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp technology and AI-linked selloffintensified by Intels weak outlook and concerns about returns on heavy AI investmentis driving attention to QQQ. Traders are split between warning of more downside and treating the drop as an oversold dip with potential for a rebound.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure amid a semiconductor and tech selloff, as traders question whether heavy AI infrastructure spending will generate adequate returns; weak Intel guidance and concerns about Amazons elevated capex are cited as contributing pressures. The community is divided between expecting a deeper unwind in the AI trade and seeing oversold conditions and technical support as possible grounds for a bounce.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas strong quarterly results and raised outlook, alongside expectations that AI agents will increase demand for identity security, fueled a sharp rally. Traders are now debating whether the growth outlook justifies the valuation, with some taking profits or positioning for a pullback.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results, supported by growth in Eylea HD and Sanofi collaboration revenue from Dupixent, drove a sharp share-price gain. Traders largely celebrated the earnings beat and breakout, while some pointed to the upcoming cemdisiran decision as another potential catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners

Equity

Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings.


A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening

A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening PR Newswire NEW YORK and TORONTO, July 21, 2026 Issued on behalf of...

ATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upside

H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.


Futures Slide After Another Korea Rout, TSMA Results Revive AI Fears

Futures Slide After Another Korea Rout, TSMA Results Revive AI Fears

 Futures are lower, erasing much of yesterday's gain with both Nasdaq and Rusell lagging SPX, following a continued rollercoaster in Korea where stocks tumbled after the BOK hired rates for the first time in 3 years...

Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026?

ATAI's 2026 rally has raised expectations as key pipeline milestones approach, leaving the stock's outlook increasingly tied to clinical execution and upcoming data.

AtaiBeckley Reflects a New Push for Rapid-Acting Mental Health Drugs

ATAI is pursuing rapid-acting mental health treatments with key late-stage catalysts ahead, but its outlook still hinges on clinical execution and pipeline progress.

AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026

ATAI enters a catalyst-heavy 2026 as BPL-003 advances toward phase III, with upcoming pipeline milestones set to shape the clinical-stage biotech's outlook.

Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity   New York, NY – June 30, 2026 – Market News Updates News Commentary – The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients relied on traditional antidepressants that often […]
The post Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity appeared first on Financial News Media.

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year PR Newswire NEW YORK and TORONTO, June 26, 2026 Issued on behalf of Helus PharmaHelus Pharma...

GH Research PLC (NASDAQ:GHRS) Given Average Recommendation of "Moderate Buy" by Brokerages

GH Research PLC (NASDAQ:GHRS - Get Free Report) has received an average recommendation of 'Moderate Buy' from the eleven research firms that are covering the firm, Marketbeat Ratings reports. One...

GH Research Plc is a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients with psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

GH Research PLC

Neutral Sentiment

<ul class="summary-bullets"><li>Wells Fargo said competition down the line could limit the long-term commercial potential of its therapy for treatment-resistant depression.</li><li>The firm initiated Helus Pharma with an ‘Overweight’ rating and a $16 price target, a near 100% upside potential from current levels.</li><li>Wells Fargo forecasts more than $7 billion in peak sales for Madrigal Pharmaceuticals’ Rezdiffra.</li></ul>Wells Fargo initiated coverage on five biotechnology companies, expressing optimism on several late-stage drug developers focused on depression therapies, including Helus Pharma (HELP), GH Research (GHRS), and Definium Therapeutics (DFTX), while taking a more cautious stance on Compass Pathways (CMPS).<h2 class="st-heading-2">Compass Could Face Competitive Challenges</h2>According to The Fly, Wells Fargo initiated Compass Pathways with an ‘Equal Weight’ rating and a $13 price target, implying a 12% upside potential from current levels.&nbsp;<a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> was up 2.6% at the time of writing.Analyst Benjamin Burnett said the company’s COMP360 therapy for treatment-resistant depression is likely to meet the U.S. Food and Drug Administration’s (FDA) approval standard after two positive Phase 3 studies. The latest trial, reported in February 2026, showed that two 25 mg doses of COMP360 delivered a statistically significant and clinically meaningful reduction in depression symptom severity, measured by the Montgomery–Åsberg Depression Rating Scale (MADRS), compared with the 1 mg dose.However, he noted that the treatment’s efficacy appears comparable to Johnson &amp; Johnson’s Spravato, while competition from follow-on therapies could limit its long-term commercial opportunity.Retail sentiment for CMPS on Stocktwits turned ‘bearish’ from ‘neutral’ a day earlier. The stock has seen strong buying interest so far this year, gaining more than 76%.<h2 class="st-heading-2">HELP Stock Has Attractive Risk/Reward Profile Ahead Of Phase 3 Results</h2>Wells Fargo initiated Helus Pharma with an ‘Overweight’ rating and a $16 price target, a near 100% upside potential from current levels.The firm thinks COMP360 data provide validation for Helus’ HLP003 in treatment-resistant depression.&nbsp;<a href="https://stocktwits.com/symbol/HELP">HELP stock</a> was up around 5% at the time of writing.Last week, Helus Pharma completed enrollment in its Phase 3 Approach Trial evaluating HLP003 in adults with moderate to severe major depressive disorder who have not responded adequately to antidepressants. The company expects to report Phase 3 results in the fourth quarter.The firm sees an attractive risk-reward profile for the shares ahead of the topline results.Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes. The stock has shed roughly 3% so far this year.<h2 class="st-heading-2">Wells Fargo Is Bullish On GH Research Despite Investor Skepticism</h2>The firm started GH Research with an ‘Overweight’ rating and a $44 price target, implying a 56% upside potential from its current levels.&nbsp;<a href="https://stocktwits.com/symbol/GHRS">GHRS stock</a> is up around 3.2%.In June, the company reported results of a Phase 2a trial for postpartum depression. The treatment met its primary endpoint, reducing depression scores by an average of 35.4 points by Day 8. The treatment was well tolerated, with no serious adverse events or treatment-related suicidal thoughts or behavior.Despite an over 12% increase in the stock price since then, Wells Fargo said the current valuation suggests investors remain unconvinced that the company’s encouraging Phase 2b depression data will be replicated in Phase 3 trials.The stock has gained more than 112% so far this year, while its retail sentiment on Stocktwits turned ‘neutral’ from ‘bullish’ a day earlier.<h2 class="st-heading-2">Definium Therapeutics Is Riding The Psychiatry Trend</h2>Wells Fargo also started coverage of Definium Therapeutics with an ‘Overweight’ rating and a $68 price target, indicating a 51% upside potential. The stock is currently up around 4%.The firm believes Spravato has validated the interventional psychiatry model for treating depression, creating room for new therapies.Definium’s lead candidate, DT120, met the primary endpoint in its Phase 3 Emerge trial in adults with major depressive disorder. Patients treated with DT120 saw a 13.3-point reduction in depression scores at six weeks, compared with a 5.2-point reduction in the placebo group. Wells Fargo believes the company is well positioned to benefit from growing demand for innovative mental health treatments.<a href="https://stocktwits.com/symbol/DFTX">DFTX shares</a> have gained more than 240% so far this year, while retail sentiment on Stocktwits has remained in the ‘bearish’ territory over the past 24 hours.<h2 class="st-heading-2">Madrigal’s Rezdiffra Has A Multi-billion-Dollar Sales Potential</h2>The firm launched coverage of Madrigal Pharmaceuticals with an ‘Overweight’ rating and a $685 price target, representing a 22% upside potential, while its stock is currently up around 3%.Wells Fargo forecasts more than $7 billion in peak sales for Rezdiffra, its lead medication to treat noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.The firm also added that physician surveys indicate concerns about GLP-1 drugs and competitive pressures are overstated, supporting durable growth in what it expects to be a ‘multi-drug market.’Retail sentiment surrounding&nbsp;<a href="https://stocktwits.com/symbol/MDGL">MDGL</a> turned ‘bullish’ from ‘neutral’ a day earlier. The stock is down around 6% so far this year.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-is-crashing-today-fda-briefing-casts-doubt-on-duchenne-cell-therapy-before-key-vote/cZZx1IOR76P">&nbsp;CAPR Stock Is Crashing Today – FDA Briefing Casts Doubt On Duchenne Cell Therapy Before Key Vote</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

While Johnson & Johnson’s stock (JNJ) has risen 25.6% so far in 2025, Roche’s U.S.-listed stock (RHHBY) has gained 20% over the same period. (Photo credit: Getty Images)

Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings.

Definium Therapeutics Inc.

Helus Pharma Inc.

Madrigal Pharmaceuticals Inc

Tema Neuroscience & Mental Health ETF

AdvisorShares Psychedelics ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$20.86
Prev Close	$21.50
Open	$21.26
Dividend Yield	0.00%
50-Day Moving Average	$24.21
Beta	1.00
Avg. Volume	278,062.06
PE Ratio	-21.78

52-Week High	$31.44
52-Week Low	$12.04
Market Capitalization	$1.48B
EPS (Annual)	-$0.7906
Price to Book	4.11
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

GHRS Fundamentals